Aliri Bioanalysis

We’re Heading to #BioEuropeSpring! ?? Join us in Milan, Italy on March 17 –19 for this exciting event focused on innovation and collaboration. ? Our colleague Camille Latapy is excited to explore new partnerships with?companies seeking powerful bioanalytical data to accelerate their drug development journey to the clinic and beyond. Request a meeting with Camille on the conference’s ParneringOne app, and click here to find our full tradeshow schedule: https://lnkd.in/eKtQjwik EBD Group

Mass spectrometry imaging (#MSI) offers a precise and detailed look into?a drug’s biological distribution and metabolites and can be an invaluable tool for improving the body of scientific evidence available to justify drug advancement into human trials. With MSI you can: ?? Speed up and optimize the drug discovery process ?? Visualize drug distribution in tissue and tissue sub-compartments ?? Analyze samples for thousands of compounds at once ?? Eliminate sensitivity and chemical alteration concerns ?? Know whether efficacy is possible based on distribution ?? Locate and identify specific metabolites to better understand potential toxicity ?? Quantify the direct target and improve understanding of pharmacokinetics (PK) and pharmacodynamics (PD) ?? Save money and provide a competitive development edge Download the infographic to learn more about the advantages of MSI and explore if this solution could be a fit for your drug development program: https://lnkd.in/eNuY_pXg #MassSpec #CRO #ScienceStrong #Infographic #DrugDevelopment

??Register Now for our Upcoming Webinar on Whole-body Pharmacokinetics! https://lnkd.in/eaNV6rHd Join us on March 20 at 11:00am ET to explore how this new label-free method enables decision-making by providing insights into efficacy at the site of action, anticipating potential safety concerns, and supporting better clinical candidate selection. #Webinar #WholeBodyPK #Pharmacokinetics #DrugDevelopment #EarlyStage #MassSpec

?? How It Works: Quantitative Mass Spectrometry Imaging (QMSI) Aliri’s QMSI spatial platform uses data analysis to conduct molecular distributions, and artificial intelligence to find patterns and make predictions. This advanced imaging technique allows you to visualize the molecule within the tissue and evaluate how prevalent the drug is within the histological region of interest. Studying drug efficacy at the site of action gives us valuable and unique insights into:? ?? Drug bioavailability???? ?? Drug biodistribution??? ?? Targeted tissue exposure???? ?? On-tissue PK/PD??? ?? Monitoring the drug effects through readout biomarkers (metabolites, lipids, genes expression, proteins)??? ? Download this helpful infographic to explore if QMSI is the right fit for your drug development program.?https://lnkd.in/evXuiKDY

We are excited to share that Aliri will be attending the upcoming ELRIG Research & Innovation conference, in London, UK, centered on innovative solutions for advanced drug modalities! Will you be attending on March 10 – 11? Reach out to schedule a meeting with our colleague, Lee Quinn, to explore how Aliri’s cutting-edge bioanalytical services and expert team can de-risk and accelerate?your drug development program. https://lnkd.in/exQXzCTx

?? Upcoming Webinar: "Whole-body Pharmacokinetics: A New and Powerful Label-Free Method to Derisk Early-Stage Drug Development." Join Aliri Lab Director, Mathieu Gaudin, Ph.D. and customer,?Hervé Giorgi, Ph.D., Non-clinical Development Director at Genfit, on March 20 to explore how?Mass Spectrometry Imaging of whole-body mice offers an effective experimental setting for comprehensive characterization of drug pharmacokinetics at an early stage, facilitating better and faster drug candidate selection. Key Takeaways: ?? Overview of Whole-Body Pharmacokinetics (PK) and its?benefits ?? How this new label-free method enables decision-making?by providing insights into efficacy at the site of action, anticipating potential safety concerns, and supporting better clinical candidate selection ?? A customer's perspective on the?implementation of this approach in their drug development strategy Register Now! https://lnkd.in/eaNV6rHd #Webinar #WholeBodyPK #Pharmacokinetics #DrugDevelopment #EarlyStage #MassSpec

?? 5 Methods for Oligonucleotide Analysis: Oligonucleotides (OGNTs) provide the opportunity to target diseases at their molecular level by manipulating gene expression. There are five main approaches to bioanalysis of OGNTs, each of which has its advantages and disadvantages: ?? LC/UV? ?? LC/MS/MS? ?? Hybridization LF/FD? ?? LC/HRMS? ?? Hybridization Elisa? ? Download this helpful infographic to learn more about each method and identify the right choice for your development program.?https://lnkd.in/eCWVQEnG #Oligonucleotides #Oligos #Bioanalysis #CRO #ScienceStrong?

?? Unlock AI-driven data that will help predict the efficacy of your molecule years earlier...before it’s too late! In a recent interview for Drug Development & Delivery magazine, Corinne Ramos, Ph.D., Director of Research & Development at Aliri Bioanalysis shares,? “Aliri’s data scientists are leveraging custom AI scripts to help our sponsors identify and better understand the drug mechanism of action at the single-cell level with far greater certainty than tradi-tional methods. The power of AI in conjunction with genomic, proteomic, and metabolomic analysis is a game-changer that provides our clients an edge when selecting drug candidates that are most likely to succeed in the clinic – while saving them time, money, and from costly mistakes in the process.” Work with our highly trained team of data scientists to de-risk and accelerate your development program to the clinic and beyond.? https://lnkd.in/e_e7yhDX

?? Small vs. large molecules: How to pick the right bioanalytical method? Appropriate testing techniques vary by molecule type, the individual characteristics of the drug, and its intended use.? Regardless of the molecule size, it is important to validate appropriate methods that can accurately determine the concentration and the bioactivity of the drug over time.? There are no regulations requiring specific methods for every drug class; instead, the goal is always to optimize the available published research and acquired data to develop scientifically appropriate methods. Download this infographic to learn more about how to choose the right method for your molecule: https://lnkd.in/e5XcqprH #SmallMolecule #LargeMolecule #bioanalysis #CRO #MethodValidation

Aliri Bioanalysis scientists at our lab in Lille, France, recently developed a composite biomarker that integrates the spatial distribution of metabolites with genomic profiling, transcending traditional methods of predicting patient responses to immuno-oncology therapy. Learn more: https://lnkd.in/euVkZhQA #SpatialBiomarkers #GenomicProfiling #PatientStratification #ImmunoOncology